Table 1:
Baseline characteristics at screening, stratified by vaccination status
| Overall (n=882) |
Unvaccinated (n=688) |
Partly vaccinated (n=55) |
Fully vaccinated (n=139) |
p value | |
|---|---|---|---|---|---|
| Age, years | .. | .. | .. | .. | 0·012 |
| 18–29 | 263 (30%) | 190 (28%) | 16 (29%) | 57 (41%) | .. |
| 30–49 | 320 (36%) | 246 (36%) | 21 (38%) | 53 (38%) | .. |
| 50–64 | 247 (28%) | 207 (30%) | 16 (29%) | 24 (17%) | .. |
| ≥65 | 52 (6%) | 45 (7%) | 2 (4%) | 5 (4%) | .. |
| Sex | .. | .. | .. | .. | 0·75 |
| Female | 506 (57%) | 390 (57%) | 33 (60%) | 83 (60%) | |
| Male | 376 (43%) | 298 (43%) | 22 (40%) | 56 (40%) | |
| Race | .. | .. | .. | .. | 0·42 |
| Asian | 28 (3%) | 18 (3%) | 4 (7%) | 6 (4%) | .. |
| Black | 116 (13%) | 89 (13%) | 10 (18%) | 17 (12%) | .. |
| Mixed or other | 17 (2%) | 15 (2%) | 0 (0) | 2 (1%) | .. |
| American Indian or Alaska Native | 15 (2%) | 14 (2%) | 0 (0) | 1 (1%) | .. |
| White | 706 (80%) | 552 (80%) | 41 (75%) | 113 (81%) | .. |
| Ethnicity | .. | .. | .. | .. | 0·11 |
| Hispanic or Latino, Latina, or Latinx | 109 (12%) | 90 (13%) | 2 (4%) | 17 (12%) | .. |
| Non-Hispanic or Latino, Latina, or Latinx | 773 (88%) | 598 (87%) | 53 (96%) | 122 (88%) | .. |
| BMI | .. | .. | .. | .. | 0·80 |
| <30·0 | 522 (59%) | 398 (58%) | 34 (62%) | 90 (65%) | .. |
| 30·0–34·9 | 179 (20%) | 141 (20%) | 9 (16%) | 29 (21%) | .. |
| ≥35·0 | 141 (16%) | 110 (16%) | 11 (20%) | 20 (14%) | .. |
| Missing | 40 (5%) | 39 (6%) | 1 (2%) | 0 (0) | .. |
| Hypertension | .. | .. | .. | .. | 0·0005 |
| No | 675 (77%) | 513 (75%) | 39 (71%) | 123 (88%) | .. |
| Yes | 207 (23%) | 175 (25%) | 16 (29%) | 16 (12%) | .. |
| Diabetes | .. | .. | .. | .. | 0·27 |
| No | 810 (92%) | 629 (91%) | 49 (89%) | 132 (95%) | .. |
| Yes | 72 (8%) | 59 (9%) | 6 (11%) | 7 (5%) | .. |
| HIV infection | .. | .. | .. | .. | 0·22 |
| No | 867 (98%) | 674 (98%) | 54 (98%) | 139 (100%) | .. |
| Yes | 15 (2%) | 14 (2%) | 1 (2%) | 0 (0) | .. |
| Asthma | .. | .. | .. | .. | 0·58 |
| No | 784 (89%) | 609 (89%) | 48 (87%) | 127 (91%) | .. |
| Yes | 98 (11%) | 79 (11%) | 7 (13%) | 12 (9%) | .. |
| Treatment group | .. | .. | .. | .. | 0·99 |
| Control | 437 (50%) | 342 (50%) | 28 (51%) | 67 (48%) | .. |
| CCP >5 days since symptom onset | 248 (28%) | 192 (28%) | 16 (29%) | 40 (29%) | .. |
| CCP ≤5 days since symptom onset | 197 (22%) | 154 (22%) | 11 (20%) | 32 (24%) | .. |
| COVID-19 wave during infection | .. | .. | .. | .. | <0·0001 |
| Pre-alpha or alpha | 704 (80%) | 642 (93%) | 46 (84%) | 16 (12%) | .. |
| Delta | 178 (20%) | 46 (7%) | 9 (16%) | 123 (88%) | .. |
| SARS-CoV-2 viral load, copies | 7248 (5909– 8889) | 8737 (6922–11 028) | 1874 (976–3598) | 4933 (2951–8246) | <0·0001 |
Data are n (%) or geometric mean (95% CI). p values were estimated using Fisher’s exact test for categorical variables and Kruskal-Wallis rank sum test for the continuous variable (SARS-CoV-2 viral load) to compare the differences between the three groups. BMI missingness is reported in the table. SARS-CoV-2 viral load had 51 missing data (unvaccinated participants n=39, partly vaccinated participants n=2, fully vaccinated participants n=10). Other variables had no missing values. CCP=convalescent plasma.